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Erythromycininduced Resistance to
Clindamycin in Staphylococcus aureus
Purpose: lb describe The incrience 01 OriotirOrny
cTh-induced resistance to c!indanii’cin in 0 sam/n/c or
Staphylococcus OLIrCUS ;soIates.
Methods: 100 ervthromycn-resstanr and cindarnu
cm-sensitive S aureus were coilectedasa convenience
sample from February to Auqisl 2003. InducThie
clindamycin resistance was idenh tied using the 0-
zone disc method.
Results: Of the 100 Staphylococcus aureus isolates,
64 were methicillin sensitive (MSSA) and 36 were
methicillin resistant (MRSA). Of the 64 MSSA isolates,
22 (34%) had inducible resistance. Of the 36 MASA
isolates, 4 (1 1%) had inducible resistance. Overall,
26% of these clindamvcin sensitive S. aureus isolates,
exhibited inducible resistance to clindamvcin,
Conclusions: In this sample, MSSA isolates were
almost three times more likely to have inducible MLS
resistance cornpared to MRSA isolates lnciucible re
sista,ice may compromise the efficacyoiciindamycin
The frequency of inducible resistance in this series of
“clindamvcin sensitive S. aureus isolates is 26%. It is
likely that the true percentage of clindamycin resistance
is being underestimated since testing for inducible
resistance is not routinely performed.
Introduction
Rates of community—acquired methicillin—resistant
Staphvlococcal aureus (MRSA caniage and infections
have been increasing. Transilioning to oral outpatient
treatment of such infectionr. especially in children.
is often limited to clindams’cin since ervthromcin.
tetracycline, and quinalone antibiotics have limited
efficacy or undesirable side effects A recent article
concluded that clindamvcin ss as eflectis e in treatmu
children with ins asivc infectionscaused b\ susceptible
communitv—acquired—MRSA isolates. Iloweser. it
should he noted that hospital acquired \IRSA isolates
are more commonl clindamvcin resistant.
Macrolides (e.g..ervthromycin). lincosamideiee.g..
clindarnvcin trade tame Cleocin). and streptogramins
(e.g.. quinupristin-dalfopristin trade name Synercid)
are antimicrobial agents active against Gram—positive
bacteria and some Gram-negative cocci. Strepto
gramins arecommonlv used inthecattle industry (e.g.,
virgimamycin). These three groups are collectively
known as “MLS” hnacrolide-lincosamide-strepto
gramin) antibiotics, They are chemically distinct. hut
alike in their mode of action, which inhibits protein
synthesis by- binding to the 50S rihosomal subunits1.
Since the introduction of ervthromvcin. macrolide—
resistant . aureus have appeared along with acquired
macrolide—resistance and resistance to other MLS
antibiotics1.Resistance to antimicrobial therapy has
become an increasing concern among physicians.
Clindamycin is more commonly employed for the
outpatient treatment of infections with suspected
Staphylococcus aureus, since methicillin/oxacillin
and cephalosporin resistance rates are rising.
The mechanism of macrohde resistance is briefly
described in the footnote helow*, But of clinical im
portance. is that some S. aureus organisms that are
clindamvcin—susceptihle and ervthromcin—resistant
based on in vitro testing. will behave as though they are
clindam cm—resistant in thepresenceofer\ throm’cin.
In other words. ervthromvcin. induces clindamsc in
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* Macrolide resistance may be due to one of three mechanisms, but the best knossn mechanism has been target
site moditication caused by methvlation of adenine nucleotides in the 23S subunit of the 50S ribosomal RNA4,
Specifically. methylation reduces the ability’ of macrol ides. lincosamides, and type—B streptograinins to bind
to the ribosomal subunits. thereb’ allowing protein synthesis to continue. In staphylococci and streptococci.
a methylating enzyme present can be repressed in sensitive bacteria, but in the presence of suhinhibitory
concentrations of macrolides. the gene that confers resistance becomes expressed and the enzvmc is induced5.
Cross—resistance between all macrolidcs. lincosamides clindamycin and lincomvcin). and strcplogramins B
pristinam ciii I. quinupristi n. and irsiniamvcin S detining the MLS,. phenotype. occurs because of overlap—
pine binding sites ot’ these antimicrobials. Although other mechanisms of resistance to macrolidcs have been
reported. rihosomal methvlation remains the most prevalent mechanism . Biochemical studies demonstrate
that the erm (erthromvcin resistance nietlivlaset genes encode the methylases that cause rihosomal modifica
tion leading to resistance.
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resistance in some of these organisms. Ervthromvcin
iN one of the most effective inducers of resistance.
hut Ii nci isam ides ( ch ndam cm have been known to
induce resistance resulting in subsequent treatment
fai nrc in patient ntections with these S. aureus iso
lates Thus. althouch the lab reports the organism as
being clindamvcin sensitive, the organism behaves
aN it it i’. clindamycin resistant. This phenomenon is
known as MLS inducible resistance, since any MLS
antibiotic can theoretically induce resistance. MIS
resistance is well known in the infectious disease
literature, but it is less well discussed in the primary
care, emergency medicine and general hospital care
literature. The purpose of this report is to determine
the lreqLiencv of er thromvcin-induced clindam cm
resistance in a sample of S. aLireus isolates in 1-lono—
lu In.
Methods
One hundred ervthromvein—resistant and clindamv—
cin-sensiti e Staphylococcus aureus isolates were
prospectively obtained from Clinical Laboratories
of Hawaii from Februar\ 2003 to August of 2003
(includes outpatient and inpatient, community and
hospital acquired). All strains were classified by sus
ceptibilities toclindamycin anderythromycin with the
Vitek system (Vitek, Hazelwood. MO). Isolates were
tested for inducible clindarnvcin-resistance using the
disc method described by Weishlum and Dernohn.
Absence of inducible resistance (true clindamcin
sensitivity) shows a normal clear zone around the
elindamycu disc, even in the presence of erythrom cm
(Figure 1). Ervthromvcin—induced resistance to clinda
mycin shows growth into the clindamycin inhibition
zone adjacent to the ersthromycin disc (Figure 2
In other words, next to the ervthromycin disk. the
clindamvcin zoneof inhibition is small,demonstrating
that the presence of erythromycin induces resistance
to clindamycin. In the absence of erythromycin. the
clindamycin inhibition zone is large. This phenomenon
is also called D-zone resistance, since the clindamycin
inhibition zone is shaped like the letter D.
Results
Of the 100 S. aureus isolates. 64 were methicil lin
sensiti\ e ( MSSA ) and 36 crc methicillin resistant
MRSA (. Of the M MSSA isolates. 22 (34fr had
inducible resistance. Of the 36 MRSA isolates. 4
II %- had inducible Overall. 26fr of these
“elindamvcin sensiti e” S. aureus isolates exhibited
erythromycin-induced resistance to clindam\ cm.
See Table 1.
Discussion
Conventional testing may be underestimating the
clindamycin resistance rate. From our data. 26h( of
S. aureus isolates sensitive to clindamycin based on
Ftgure 2 Presence of MLS tnducible resistance.
o zone resistance
Here. t5e erythromycin disc is on me :ett and the chndamycin disc iS Ofl
the rig-it. The ctndamycin zone of nhibition is blunted on the left side
of the chndamycin disc resembling the letter’ D i This is an example
of inducible clindamycin resistanceo,7. in which clindamycin resistance
is induced by the presence of eryth. omycin.
Tab.e I.— MLS resistance rates among MSSA and MRSA isolates
D-zone Phenomenon
(MLS resistance)
22
Total isolates
MSSA MRSA
Percent inducible resistance
64
34%
4
36
11%
Table 2.— Clindamycin resistance rates among S. aureus isolates in Honolulu
Year Clindamycin-resistance rate
999 2°
2000 4%
2001 5%
2002 8%
2003 15%
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conventional testing. exhibited clindam cm resistance in the presence
of erythromycin. Data compansons between methicil un—sensitive
(MSSA) and methicil I in—resistant S. aureus (M RSA), suggest that
MSSA isolates are three-times more likely to have inducihie—resis
tanee than MRSA.
There have been recent case reports of inducible-resistance of
staphylococcal isolates during therapy while on clindarncin1.
Overall, organisms are becoming increasingly resistant to current
antibiotics despite attempted changes in physician prescribing be
havior, In Honolulu, clindarnycin resistance rates for S. aureus have
slowly risen. Data obtained from Clinical Laboratories of Hawaii
show that clindamycin—resislance in S. aureus was 2f% in 1999 (see
Table 2). In 2003. clindarnycin—resistant S. aureus isolates increased
to I 5ff a seven-fold increase over 5 years. The in vivo resistance
rates are likely to be higher than this since inducible resistance is not
detectable by conventional antibiotic sensitivity determinations.
We did not examine the clinical records of these patients. Nor did
we stratify the S. aureus isolates by age group. specimen source or
inpatient/outpatient. Furthermore, the isolates were not tested for
the erm gene (see footnote*). Thus we were unable to definitively
determine whether the inducible resistance was due to methylation
or from one of the less common mechanisms27.
MRSA comprises approximately 25% of S. aureus isolates in
Honolulu. reducing the efficacy rate of anti—staphylococcal penicil—
lins (e.g.. methicillin, oxacillin. dicloxacillin) and cephalosporins.
Clindamycin is an available oral alternative for S. aureus infections.
Trimethoprim-sulf’amethoxazole, doxycycline (notsuitable foryoung
children). rifampin and the very expensive drug, linezolid are other
alternatives. Since the differential of causative microbial agents for
soft tissue infections, often includes group A beta hemolytic strep
tococci (GABHS) and S. aureus together. clindamycin potentially
covers these two well. The potential for inducible resistance to
clindamycin reduces the efficacy certainty of clindamycin therapy.
Additionally, inducible MLS inducible resistance is also exhibited
by strains of GABHS’.
Increasing awareness of inducible resistance should be brought
to the attention of primary care physicians, emergency physicians
and hospital based physicians. treating potentially serious S. aureus
infections such as cellulitis, septic arthritis, osteomyelitis. abscesses.
staphylococcal pneumonia. bronchiectasis. bacterial endocarditis,
bacterial pericarditis, etc. For serious and life—threatening infections
with S. aureus. clindamycin’s sensitivity rate is not good enough. The
potential for inducible resistance further compromises the efficacy
of clindamycin. Once the organism is identified, if clindamycin
therapy is being considered. clindamycin sensitivity testing should
ideally include testing for inducible resistance since conventional
testing does not identify inducible resistance.
Additionally. there sh uld be more judicious use (i.e.. less use) of
macrohdes (e.g ..azithromycin and clarithrom cm) and clindamycin
since both have been implicated as inducers of the resistance in S.
aureus. However, an ideal practice parameter to determine appropri
ate use is difficult to develop.
Pediatric data suggests that community acquired MRSA can be
treated with clindamycinL hut this has the potential for the develop
ment of inducible resistance and possible treatment failure while
on therapy5.In summary, inducible resistance to clindamycin may
compromise the efficacy of clindamycin. The frequency of induc
ible resistance in this series of “clindamycin sensitive” S. aureus
isolates is 26ff . It is likely that the true percentage of clindamycin
resistance is being underestimated since testing fbr inducible MLS
resistance is not routinely performed.
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